Sage Journals: Discover world-class research

Abstract

Type 1 insulin-like growth factor receptor (IGF1R) signalling plays a critical role in normal cell growth, and in cancer development and progression. IGF1R and the insulin-like growth factors 1 and 2 (IGF1 and IGF2) are involved in various aspects of the malignant phenotype, suggesting that IGF1R is a potential target for cancer therapy. IGF1R is particularly important in the establishment and maintenance of the transformed phenotype, in mediating proliferation, and for the survival of tumour cells with anchorage-independent growth. IGF1R also exerts antiapoptotic activity and has a substantial influence on the control of the cell and body size. This property enables transformed cells to form macroscopic tumours and to survive the process of detachment required for metastasis. Pharmaceutical companies are investigating molecules that target IGF1R, including specific low molecular weight tyrosine kinase inhibitors and monoclonal antibodies, both of which possess various advantages and display different activity profiles. This review article focuses on the preclinical and clinical development of low molecular weight IGF1R tyrosine kinase inhibitors. It is critical to pursue a thorough molecular analysis of the metabolic activity of IGF1R to avoid possible side-effects of its inhibition.

Keywords

IGF1 IGF1R tyrosine kinase inhibitor cancer

Introduction

Cell growth and proliferation are regulated by complex signalling systems involving intrinsic factors and external stimuli. Insulin-like growth factors (IGFs) and their receptors comprise a signalling system required for G₁/S phase cell-cycle progression and cell division.¹ The IGF system includes three ligands – IGF1, IGF2 and insulin – that interact with type 1 insulin-like growth factor receptor (IGF1R),² IGFR2 and the insulin receptor (IR).³ IGF1R is an attractive target for cancer therapy as its abnormal expression is associated with tumourigenesis, metastasis and treatment resistance.⁴ Various strategies have been used to target IGFR1 in animal and human tumour cell lines and animal models, some of which may be advancing to clinical use.⁵ The three main approaches are receptor blockade with monoclonal antibodies, tyrosine kinase inhibition, and ligand neutralization via monoclonal antibodies targeted to ligand or recombinant IGF binding proteins (IGFBPs).⁶ Monoclonal antibodies directed against IGF1R cannot block the binding of both IGF1 and IGF2, nor can they downregulate both IGF1R homoreceptor and hybrid receptor pairs.⁷ Tyrosine kinase inhibitors indiscriminately inhibit the kinase domains of all IGF system receptors, however.⁸ This review will focus on the role of the IGF1R signalling pathway in cancer, and the preclinical tyrosine kinase inhibitor data that will likely guide the future development of such therapy.

IGF1R signalling pathway

System components

Homoreceptors

The tetrameric transmembrane receptor tyrosine kinase IGF1R was identified in 1986.² In humans, it is encoded by the IGF1R gene, which contains an open reading frame of 4101 nucleotides encoding a 1367 amino acid protein.⁹ IGF1R is synthesized as a single chain pre-propeptide, with a 30-amino acid signal peptide that is cleaved after translation of the nascent polypeptide chain. The propeptide is then glycosylated, dimerized, and transported to the Golgi where it is processed at a furin cleavage site, yielding α- and β-subunits.^2,10 The mature membrane-bound IGF1R is composed of two extracellular 130 kDa α-chains responsible for ligand binding, and two 98 kDa β-chains, comprising a transmembrane domain and a cytoplasmic tyrosine kinase domain, formed of several α–α and α–β disulphide bridges.¹¹ The α- and β-subunits contain 11 and five potential N-linked glycosylation sites (required for IGF1R translocation to the cell surface), respectively.¹² IGF1R is transported to the cell membrane as a fully assembled dimer.¹³

The intracellular domain of the β-subunit includes a binding site for phosphorylated substrates at Tyr⁹⁵⁰ with a role in signal transmission, a tyrosine kinase domain with an ATP-binding site at lysine¹⁰⁰³, three critical tyrosines at positions 1131, 1135 and 1136, and a C-terminal domain containing several phosphorylated tyrosine and serine residues (such as Tyr¹²⁵⁰, Tyr¹²⁵¹, Tyr¹³¹⁶ and Ser^1280–1283) that play roles in IGF1R signalling.¹⁴

Hybrid receptors

Both IR and IGF1R evolved from the same receptor concerned with the regulation of longevity, metabolism and organism size.¹⁵ Since IGF1R is highly homologous to the IR, sharing 84% amino acid identity in the kinase domain and near absolute conservation in the ATP binding pocket,¹⁶ IR and IGFR proreceptors may heterodimerize to form insulin–IGF hybrid receptors, comprising one α-subunit and one β-subunit each of the IR and IGF1R.^17–20 Further complexity arises from the existence of two isoforms of the IR, IR-A and IR-B, each of which can associate with IGF1R to form IR-A/IGF1R and IR-B/IGF1R hybrids. IR-B/IGF1R hybrids have a higher affinity for IGF1, whereas IR-A/IGF1R hybrids have equal affinity for IGF2 and insulin.²⁰ These hybrid heterodimeric receptors could play a role in receptor signalling in normal and abnormal tissues.²¹ Research in the human breast cancer cell line MDA-MB157 showed that autophosphorylation of IR/IGF1R hybrid receptors in response to IGF1 exceeded that of IGF1R homoreceptors and led to increased cell proliferation, indicating that hybrid receptors were the major mediators of IGF signalling in these cells.²¹

Ligands

The mitogenic and antiapoptotic effects of IGF1 and IGF2 are mediated by IGF1R.²² IGF1 and IGF2 are produced by the liver and by extrahepatic sites including tumour cells and stromal fibroblasts.²³ IGFs are single chain polypeptides, comprising A-, B-, C- and D-domains, with high affinity binding to IGF1R being localized to the C-domain. The absence of Thr^A8, IleA¹⁰, His^B5 and Tyr^B16 contact points in the A- and B-domains of the IR may be responsible for the weak binding affinities of IGF1 and IGF2 for the insulin receptor.²⁴ IGF1 and IGF2 share a 62% homology in amino acid sequence, with a 40% homology between the IGFs and proinsulin.²⁵ The binding affinity for IGF1R varies under different experimental conditions and cell types.²⁶ Relative concentrations of IGF1 and IGF2 also vary, with IGF2 concentrations being five times higher than IGF1 levels in human foetuses, and 3.5 times higher in adult sera.²⁷

Also present in the cellular microenvironment are six IGF binding proteins (IGFBP1–6) that regulate the bioavailability of IGFs by competing with IGFRs, and IGFBP proteases that modulate the balance between IGFs and IGFBPs.²⁸ IGFBPs and IGFs comprise a major superfamily of protein hormones that regulate mitogenesis, differentiation, survival and other IGF-stimulated events in both normal and cancerous cells.^29,30 An in vivo study indicated that IGFBP3 inhibits the growth of HER2-overexpressing breast tumours and potentiates herceptin activity.³¹ Others have found, however, that high IGFBP2 expression was not associated with reduced cell proliferation in breast cancer, glioblastoma or prostate cancer.^32–34 These data suggest that IGFBPs can affect cell function in an independent manner, but their role in cancer is not yet clear.³⁵

IGF1R signal transduction

The binding of IGF1, IGF2 or insulin to IGF1R leads to the autophosphorylation of tyrosines 1131, 1135 and 1136 in the kinase domain on the intracellular portion of the β-subunits, inducing the phosphorylation of juxtamembrane tyrosines and carboxyl-terminal serines.³⁶ Subsequently, the juxtamembrane Tyr⁹⁵⁰ serves as a binding site for docking proteins including IR substrates 1–4 (IRS1–IRS4), and Src homology/collagen domain protein (SHC). These substrates initiate the PI3K/Akt (phosphatidylinositol 3-kinase/protein kinase B) and RAS/RAF/MEK/ERK signalling pathways, transmitting the IGF1R signal.³⁷

Phosphorylated IRS1 recruits the regulatory and catalytic subunits of PI3K, ultimately resulting in the downstream phosphorylation of Akt at Thr³⁰⁸.^38,39 It is well known that Akt plays a critical role in controlling survival and apoptosis.³⁹ Akt phosphorylation enhances the protein synthesis required for cell proliferation via the mammalian target of rapamycin complex, triggers the antiapoptotic effects of IGF1R through the phosphorylation and inactivation of Bcl-xL/Bcl-2 associated death promoter and the inactivation of caspase 9, and also stimulates cell growth through the inhibitory phosphorylation of growth factors (including forkhead box proteins, p21, p27, Chk1, and glycogen synthase kinase 3 [GSK3]).³⁸

In parallel to PI3K-driven signalling, the recruitment of growth factor receptor-bound protein 2 (Grb2)/SOS by either phosphorylated IRS1 or SHC leads to IGF1R signal transmission via the RAS/RAF/MEK/ERK pathway.⁴⁰ The Grb2/SOS complex activates the signalling pathway, resulting in the downstream phosphorylation and activation of MKK and ERK.⁴¹ Activated ERK induces cell proliferation by the phosphorylation of nuclear transcription factors such as Ets-like transcription factor-1 (Elk-1) and c-Fos.⁴² Activated MKK phosphorylates p38, and is responsible for inducing cell proliferation via the activation of c-Myc, JNK, and subsequently c-Jun.⁴³

Cell-cycle progression is positively regulated by IGF1R signalling through cycle checkpoints in several phases. It increases ribosome activity through activation of p70S6K and S6 to facilitate the transition from G₀ to G₁,⁴⁴ increases the expression of cyclin D₁ to facilitate the G₁/S transition⁴⁵ and may increase cyclins A and B and cdc2 synthesis to promote the G₂/M transition.⁴⁶ The major direct effect of the IGF1R mediated signal is most likely exerted at the G₁/S interface, however.⁴⁷

IGF1R: A target for cancer therapy

Emerging evidence implicates IGF1R signalling in the development and progression of cancer. IGF1R, IGF1 and IGF2 are involved in various aspects of the malignant phenotype, suggesting that IGF1R may be a target for cancer therapy.

IGF1R signalling in normal physiology

It is known that IGF1R protects cells from apoptosis, while promoting proliferation and cell growth. Newborn mice lacking IGF1 or IGF2 were found to be significantly smaller (60% of normal birth weight) than wild-type mice, and IGF1R knockout mice were even smaller (45% of normal size), confirming that IGF and its receptor play a role in normal growth.⁴⁸ Mice with double IR/IGF1R deficiency in both cardiac and skeletal muscle die early from heart failure, due to the co-ordinated effects of IR/IGF1R on the downregulation of electron transport and mitochondrial fatty acid β-oxidation.⁴⁹ IGF signalling from these receptors is therefore essential for normal cardiac metabolism and function. IGF1R also plays a role in embryonic bone development.⁵⁰ Studies of IGF1R signalling in the nervous system have shown that IGF signalling promotes differentiation and proliferation, and sustains survival by preventing apoptosis of neuronal and brain derived cells in vitro.⁵¹ Other studies have shown that IGF1R regulates cell lifespan, adhesion and motility, and can induce differentiation in specific cellular contexts.⁵² The role of IGF1R in normal physiology appears to be more complex than was thought when this protein was initially identified.

IGF-IR signalling in malignancy

It has been shown that IGF1R, its ligands and IGFBPs are highly expressed in prostate,⁵³ breast,⁵⁴ colorectal⁵⁵ and pancreatic cancers,⁵⁶ melanoma,⁵⁷ multiple myeloma,⁵⁸ mesothelioma,⁵⁹ glioblastoma⁶⁰ and childhood malignancies.²⁷ IGFs and IGF1R regulate all aspects of the malignant phenotype.⁶¹

Studies show a correlation between circulating IGF1 levels and cancer risk in some malignancies (premenopausal breast, prostate and colorectal carcinomas, as well as lung, endometrial and bladder cancers).²⁸ Individuals with high serum IGF1 concentrations and/or lower levels of IGFBPs had more than twice the risk of developing cancer than those at the low end of the normal range.⁶¹ Other studies have failed to indicate consistent correlations, for example circulating IGF1, IGFBP1, IGFBP3 and growth hormone levels were found to have no association with breast cancer risk in a large cohort of premenopausal women.⁶²

Type 1 insulin-like growth factor receptor plays an important role in the establishment and maintenance of the transformed phenotype. It is not unique in driving tumour cell proliferation, but is essential in the mediation of proliferation and survival of tumour cells with anchorage-independent growth.⁶³ IGF1R also exerts antiapoptotic activity and has a significant influence on the control of cell and body size.⁶³ This property enables transformed cells to form macroscopic tumours, and to survive the process of detachment that is required for metastasis.⁶⁴ Data from in vitro and in vivo studies have confirmed the importance of the IGF1R system in cancer growth and metastasis. Treatment of synovial sarcoma cell lines with the IGF1R antagonist NVP-AEW541 led to increased apoptosis, and impaired growth, mitotic activity and cell migration.⁶⁵ IGF1R did not enhance motility in LCC6-DN cells (a breast cancer cell line with dominant negative IGF1R), in contrast to increased motility in wild-type LCC6 cells, suggesting that metastasis is inhibited by truncated IGF1R.⁶⁶ The injection of mice with LCC6, but not LCC6-DN, cells resulted in the formation of lung metastases, indicating that IGF1R regulates metastasis independently from tumour growth.⁶⁶ Using a similar approach, human KM12L4 colon cancer xenograft tumours induced in nude mice were significantly smaller when the KM12L4 cells were transfected with a truncated dominant-negative form of IGF1R than when using wild-type cells.⁶⁷ In addition, the colon cancer cells with dominant negative IGF1R failed to produce liver metastases after splenic injection.⁶⁷ These findings suggest that IGF1R plays an important role in the metastasis of cancer cells.

Type 1 insulin-like growth factor mediates proliferation, motility and apoptosis protection in cancer, and represents a promising target for cancer therapy. Clinical trials are required to examine this treatment potential fully.

Targeting the IGF system for cancer therapy

The critical role of IGF signalling in initiating and promoting tumour progression has resulted in it becoming an attractive target for cancer therapy. Various strategies have been used to target components of this system both in vitro and in vivo, some of which have advanced to clinical use.⁴ The general aim of these approaches is to interfere with the function of IGF system components by methods including small interfering RNA, antisense oligonucleotides, antisense RNA, triple helix-forming oligodeoxynucleotides, specific kinase inhibitors, single chain antibodies and fully humanized anti-IGF1R monoclonal antibodies.⁴ The neutralization of natural ligands can also inhibit IGF1R activation. There are three ways to neutralize IGF action: the overexpression of IGF2R⁶⁸ and IGFBP1⁶⁹; the use of soluble IGF1R (e.g. IGF1R⁹³³);⁷⁰ and antibodies against IGF2 and IGF2 (such as the rat monoclonal antibody, KM1468).⁷¹ These studies demonstrated that functional interference of IGF1R leads to the inhibition of cancer cell proliferation, survival, anchorage-independent growth in vitro, tumour growth and metastasis, and sensitizes cancer cells to various kinds of radiation and chemotherapeutic regimens in vivo.

IGF1R tyrosine kinase inhibitors

The two most thoroughly investigated strategies for IGF1R inhibition are small-molecule tyrosine kinase inhibitors and monoclonal antibodies, both of which have various advantages and display different activity profiles. Studies have concentrated on modulating IGF1R tyrosine kinase activity by targeting its intracellular kinase domain. The high sequence homology of the kinase domains of IGF1R and IR² has complicated the design process for an IGF1R specific low-molecular weight tyrosine kinase inhibitor. Table 1 lists nine IGFR1 kinase-specific inhibitors at different stages of development.⁷²

Table 1.

Class and trial status of type 1 insulin-like growth factor receptor (IGFR1) tyrosine kinase inhibitors currently under developmen.

Drug name	Company	Class	Trial status
INSM-18	Insmed UCSF	Reversible ATP-competitive	Phase I/II
OSI-906	OSI Pharmaceuticals	Oral small molecule Reversible ATP-competitive	Phase I
XL-228	Exelixis	Oral small molecule	Phase I
NVP-ADW742	Novartis	Reversible ATP-competitive	Preclinical
NVP-AEW541	Novartis	Reversible ATP-competitive	Preclinical
AG-1024	Merck	Non ATP-competitive	Preclinical
BMS-536924	Bristol-Myers Squibb	ATP-competitive	Preclinical
BMS-554417	Bristol-Myers Squibb	Oral small molecule Reversible ATP-competitive	Preclinical
BVP-51004 (Cyclolignan PPP)	Karolinska Cancer Institute Biovitrum	Oral small molecule Non ATP-competitive	Preclinical

Small-molecule tyrosine kinase inhibitors can be given orally and are able to cross the blood–brain barrier, but may result in drug–drug interactions or overlapping toxicities when used in combination with other agents.⁷³ In addition, small-molecule tyrosine kinase inhibitors may be associated with more serious metabolic adverse effects than monoclonal antibodies, as they can affect both IR and IGF1R signalling.⁷⁴ An advantage of small-molecule IGF1R tyrosine kinase inhibitors over antibodies is their wider range of inhibition due to the frequent expression of IR in tumours, hyperinsulinism in aggressive cancers, and IR-mediated resistance to IGF1R-targeted therapy, all of which may enhance antineoplastic activity.⁷⁵

Combination therapy with either cytotoxic (chemotherapy or radiation) or cytostatic treatments and tyrosine kinase inhibitors has been shown to increase the effect of inhibitors, as IGF1R is closely associated with apoptosis, cell survival and radiation, and chemotherapy resistance. For example, combination treatment with the IGFR1 tyrosine kinase inhibitor NVP-AEW541 and cytostatics such as doxorubicin or fluvastatin resulted in additive antineoplastic effects in gastrointestinal neuroendocrine tumour (NET) cells.⁷⁶ In addition, NVP-AEW541 in combination with IGFBP3 abrogated IGF1 responses at 10-fold lower doses than either compound alone in human head and neck squamous cell carcinoma (HNSCC).⁷⁷ These findings suggest that combination treatment may be a promising approach in IGF1R targeted therapy, but this requires further investigation.

There are two categories of IGF1R tyrosine kinase inhibitor. The most common are ATP antagonists (INSM-18, OSI-906, NVP-ADW742, NVP-AEW541, BMS-536924 and BMS-554417), with non-ATP antagonists also under development (BVP-51004 [PPP] and AG-1024). In vitro pharmacological studies have found variations in the selectivity of these molecules for IGF1R over IR. OSI-906, INSM-18, picropodophylin and NVP-AEW541 appear to be more selective for IGF1R, and BMS-554417 has equivalent potency towards both receptors. The different selectivity for each receptor defines a specific therapeutic opportunity for each drug.

INSM-18

The orally available molecule INSM-18 directly inhibits the human epidermal growth factor receptor c-erbB2/HER2/neu and IGF1R tyrosine kinase.⁷² INSM-18 was discovered by the University of California, San Francisco and is currently being developed with Insmed (Monmouth Junction, NJ, USA). Its IGF1R inhibitory mechanism is unclear. INSM-18 may also induce apoptosis, inhibit arachidonic acid 5-lipoxygenase and prevent the release of reactive oxygen species.⁷² The antitumour activity of INSM-18 has been demonstrated in breast, lung, pancreatic and prostate tumour preclinical studies.⁷² INSM-18 had a good safety profile and was well tolerated in two single-dose phase I clinical studies in healthy volunteers.⁷² A dose-escalating phase I/II clinical study has been completed by the University of California, the results of which will be used to design a phase II clinical study.⁷²

NVP-AEW541

The low molecular weight molecule NVP-AEW541 is a pyrrolo[2,3-d]pyrimidine derived kinase inhibitor with a higher selectivity for IGF1R (50% inhibitory concentration [IC₅₀] 0.086 µM) than IR (IC₅₀ 2.3 µM) in cellular assays.⁷⁸ Preclinical studies are ongoing, but its antitumour activity has been demonstrated in musculoskeletal tumours,⁷⁹ hepatocellular carcinoma,⁸⁰ NET,⁷⁶ malignant mesothelioma,⁸¹ HNSCC,⁷⁷ colorectal cancer,⁸² neuroblastoma,⁸³ Ewing's sarcoma,⁸⁴ multiple myeloma,⁸⁵ pancreatic cancer,⁸⁶ gastrointestinal stromal tumour,⁸⁷ gastrointestinal cancer,⁸⁸ breast cancer⁸⁹ and synovial sarcoma.⁶⁵ As expected for a specific IGF1R kinase inhibitor, NVP-AEW541 abrogated IGF1-mediated survival, inhibited the proliferation of cultured tumour cell lines by inducing apoptosis and cell cycle arrest in vitro, and significantly inhibited the growth of tumour xenografts in vivo.^{65,76,77,79–89} Accumulating evidence suggests that NVP-AEW541 represents a potential therapeutic strategy for the treatment of tumour types in which IGF1R-mediated signalling is required for driving/survival.

BVP-51004

The non ATP antagonist BVP-51004 (cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]-1-(2-phenyl-quinolin-7-yl)-imidazo [1,5-a]pyrazin-8-ylamine, also known as PPP and PQIP) was originally identified at the Karolinska Cancer Institute (Sweden) and is currently being developed by Swedish Orphan Biovitrum (Stockholm, Sweden). BVP-51004 inhibits IGF1R autophosphorylation with 14-fold selectivity relative to IR, via inhibition of the phosphorylation of Tyr¹¹³⁶ in the kinase activation loop, stabilizing the activation loop conformation.^90,91 It has been demonstrated that BVP-51004 preferentially inhibits the PI3K-Akt pathway, and blocks the growth of a variety of tumours, both in vitro and in vivo.⁹² A study in human colorectal cancer cells indicated that BVP-51004 is a selective IGF1R kinase inhibitor that is highly effective in IGF2-driven tumours.⁵⁹

Conclusions

Multiple lines of evidence indicate that the IGFR1 signalling system plays a critical role in carcinogenesis, and high concentrations of IGF1R and its ligands are predictive of increased cancer risk. Pharmaceutical companies are investigating candidate drugs that target IGF1R, and early clinical data are encouraging. Ongoing trials will determine the relative safety and efficacy of IGF1R tyrosine kinase inhibitors and monoclonal antibodies. Research is required to identify the most rational combination therapies, which may also provide information for future clinical trial designs. It is critical to pursue a thorough molecular analysis of the metabolic activity of IGF1R in order to avoid possible side-effects of its inhibition.

Footnotes

Declaration of conflicting interest

The author declares that there are no conflicts of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

Cross

Dexter

. Growth factors in development, transformation, and tumorigenesis. Cell 1991; 64: 271–280.

Ullrich

Gray

Tam

. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that deﬁne functional speciﬁcity. EMBO J 1986; 5: 2503–2512.

Belfiore

. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007; 13: 671–686.

Heidegger

Pircher

Klocker

. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther 2011; 11: 701–707.

Hofmann

García-Echeverría

. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005; 10: 1041–1047.

Arnaldez

Helman

. Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am 2012; 26: 527–542.

Ewing

Goff

. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 2010; 9: 219–223.

Takeuchi

Ito

. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 2011; 34: 1774–1180.

LeRoith

Werner

Beitner-Johnson

. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143–163.

10.

Adams

Epa

Garrett

. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57: 1050–1093.

11.

Massagué

Czech

. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem 1982; 257: 5038–5045.

12.

Werner

LeRoith

. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68: 183–223.

13.

Carlberg

Dricu

Blegen

. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem 1996; 271: 17453–17462.

14.

Favelyukis

Till

Hubbard

. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001; 8: 1058–1063.

15.

Browner

Kahn

Ziv

. The genetics of human longevity. Am J Med 2004; 117: 851–860.

16.

Munshi

Hall

Kornienko

. Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution. Acta Crystallogr D Biol Crystallogr 2003; 59: 1725–1730.

17.

Moxham

Duronio

Jacobs

. Insulin-like growth factor I receptor β-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 1989; 264: 13238–13244.

18.

Soos

Siddle

. Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. Biochem J 1989; 263: 553–563.

19.

Treadway

Morrison

Goldﬁne

. Assembly of insulin/insulin-like growth factor-1 hybrid receptors in vitro. J Biol Chem 1989; 264: 21450–21453.

20.

Pandini

Frasca

Mineo

. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277: 39684–39695.

21.

Pandini

Vigneri

Costantino

. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999; 5: 1935–1944.

22.

Vincent

Feldman

. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res 2002; 12: 193–197.

23.

Chen

Boyartchuk

Lewis

. Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia 2009; 11: 835–845.

24.

Gauguin

Klaproth

Sajid

. Structural basis for the lower affinity of the insulin-like growth factors for the insulin receptor. J Biol Chem 2008; 283: 2604–2613.

25.

Fürstenberger

Senn

. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298–302.

26.

Danielsen

Larsen

Gammeltoft

. Chromaffin cells express two types of insulin-like growth factor receptors. Brain Res 1990; 518: 95–100.

27.

Bennett

Wilson

Liu

. Levels of insulin-like growth factors I and II in human cord blood. J Clin Endocrinol Metab 1983; 57: 609–612.

28.

Kalus

Zweckstetter

Renner

. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J 1998; 17: 6558–6572.

29.

Firth

Baxter

. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824–854.

30.

Sitar

Popowicz

Siwanowicz

. Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci USA 2006; 103: 13028–13033.

31.

Jerome

Alami

Belanger

. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2–overexpressing breast tumors and potentiates Herceptin activity in vivo. Cancer Res 2006; 66: 7245–7252.

32.

Levitt

Eigl

. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008; 14: 6944–6954.

33.

Mehrian-Shai

Chen

Shi

. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007; 104: 5563–5568.

34.

Levitt

Georgescu

Pollak

. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 2005; 336: 1056–1061.

35.

Perks

Holly

. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia 2008; 13: 455–469.

36.

Pourpak

Morris

. Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach J Med Chem. 2009; 52: 4981–5004.

37.

Shelton

Steelman

White

McCubrey

. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 2004; 3: 372–379.

38.

Sarbassov

Guertin

Ali

. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098–1101.

39.

Jacinto

Facchinetti

Liu

. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125–137.

40.

Perrini

Laviola

Carreira

. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol 2010; 205: 201–210.

41.

Chen

Water

Holt

. SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J Biol Chem 1996; 271: 6328–6332.

42.

Buchwalter

Gross

Wasylyk

. Ets ternary complex transcription factors. Gene 2004; 324: 1–14.

43.

Mittelstadt

Salvador

Fornace

Jr . Activating p38 MAPK: new tricks for an old kinase. Cell Cycle 2005; 4: 1189–1192.

44.

Sunami

Byrne

Diehl

. Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation. J Biol Chem 2010; 285: 4587–4594.

45.

Tognon

Sorensen

. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 2012; 16: 33–48.

46.

Mahmoudabady

Mathieu

Touihri

. Cardiac insulin-like growth factor-1 and cyclins gene expression in canine models of ischemic or overpacing cardiomyopathy. BMC Cardiovasc Disord 2009; 9: 49–49.

47.

Samani

Yakar

LeRoith

. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20–47.

48.

Liu

Baker

Perkins

. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75: 59–72.

49.

Laustsen

Russell

Cui

. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol 2007; 27: 1649–1664.

50.

Nakae

Kido

Accili

. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 2001; 22: 818–835.

51.

Russo

Gluckman

Feldman

. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005; 26: 916–943.

52.

Romano

. The complex biology of the receptor for the insulin-like growth factor-1. Drug News Perspect 2003; 16: 525–531.

53.

Pandini

Genua

Frasca

. Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway. Ann N Y Acad Sci 2009; 1155: 263–267.

54.

Tamimi

Colditz

Wang

. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat 2011; 128: 243–250.

55.

Shan

Zhang

. Expression of IGF-1R in colorectal polyps and its role in colorectal carcinogenesis. Technol Cancer Res Treat 2011; 10: 381–389.

56.

Nair

De Armond

Adamo

. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 2001; 20: 8203–8214.

57.

Al-Jamal

Kivelä

. Prognostic associations of insulin-like growth factor-1 receptor in primary uveal melanoma. Can J Ophthalmol 2011; 46: 471–476.

58.

Meissner

Seckinger

Rème

. Gene expression profiling in multiple myeloma – reporting of entities, risk, and targets in clinical routine. Clin Cancer Res 2011; 17: 7240–7247.

59.

Kalra

Zhang

. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell. Int J Cancer 2012; 131: 2143–2152.

60.

Bielen

Perryman

Box

. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. Mol Cancer Ther 2011; 10: 1407–1418.

61.

Sachdev

Singh

Fujita-Yamaguchi

. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006; 66: 2391–2402.

62.

Schernhammer

Holly

Hunter

. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006; 13: 583–592.

63.

Valentinis

Baserga

. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54: 133–137.

64.

Baserga

Peruzzi

Reiss

. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107: 873–877.

65.

Friedrichs

Küchler

Endl

. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 2008; 216: 428–439.

66.

Sachdev

Hartell

Lee

. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2004; 279: 5017–5024.

67.

Reinmuth

Fan

Liu

. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002; 82: 1377–1389.

68.

Lee

Weiss

Martin

. Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int J Cancer 2003; 107: 564–570.

69.

Zhang

Yee

. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res 2002; 62: 4369–4375.

70.

Chen

Feng

Zhao

. Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics. Mol Cancer Ther 2012; 11: 1400–1410.

71.

Goya

Miyamoto

Nagai

. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004; 64: 6252–6258.

72.

Rodon

DeSantos

Ferry

Jr . Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7: 2575–2588.

73.

Yin

Girnita

Strömberg

. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 2010; 12: 19–27.

74.

Arora

Scholar

. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971–979.

75.

Pollak

. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 2008; 22: 625–638.

76.

Höpfner

Baradari

Huether

. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 2006; 13: 135–149.

77.

Slomiany

Black

Kibbey

. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett 2007; 248: 269–279.

78.

García-Echeverría

Pearson

Marti

. In vivo antitumor activity of NVP-AEW541 – a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231–239.

79.

Scotlandi

Manara

Nicoletti

. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65: 3868–3876.

80.

Höpfner

Huether

Sutter

. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 2006; 71: 1435–1448.

81.

Whitson

Jacobson

Frizelle

. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. Ann Thorac Surg 2006; 82: 996–1002.

82.

Höpfner

Sutter

Huether

. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 2006; 12: 5635–5643.

83.

Tanno

Mancini

Vitali

. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 2006; 12: 6772–6780.

84.

Manara

Landuzzi

Nanni

. Preclinical in vivo study of new insulin-like growth factor-I receptor–specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007; 13: 1322–1330.

85.

Maiso

Ocio

Garayoa

. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol 2008; 141: 470–482.

86.

Moser

Schachtschneider

Lang

. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer 2008; 44: 1577–1586.

87.

Tarn

Rink

Merkel

. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008; 105: 8387–8392.

88.

Piao

Wang

Adachi

. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther 2008; 7: 1483–1493.

89.

Lisztwan

Pornon

Chen

. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res 2008; 10: R56–R56.

90.

Girnita

Del Prete

. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004; 64: 236–242.

91.

Vasilcanu

Girnita

. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004; 23: 7854–7862.

92.

Mulvihill

Rosenfeld-Franklin

. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo. Mol Cancer Ther 2007; 6: 2158–2167.

The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer

Abstract

Keywords

Introduction

IGF1R signalling pathway

System components

Homoreceptors

Hybrid receptors

Ligands

IGF1R signal transduction

IGF1R: A target for cancer therapy

IGF1R signalling in normal physiology

IGF-IR signalling in malignancy

Targeting the IGF system for cancer therapy

IGF1R tyrosine kinase inhibitors

INSM-18

NVP-AEW541

BVP-51004

Conclusions

Footnotes

Declaration of conflicting interest

Funding

References